BioReliance Licenses B-CLEAR Technology from Qualyst Transporter Solutions for Drug Transporter Studies
![](/46/pdcnewsitem/03/44/13/uLsEg4UY5OnsQAq.png)
BioReliance, Sigma-Aldrich Corporation's biologics and early-development services business under SAFC Commercial, has announced a non-exclusive license agreement with Qualyst Transporter Solutions (QTS) for its proprietary B-CLEAR technology. Used in conjunction with BioReliance technologies, B-CLEAR enables researchers to assess drug disposition and drug interactions within complex, whole-cell liver systems.
When applied to properly functioning hepatic cells, B-CLEAR opens the bile pockets (analogous to bile canaliculi in vivo), allowing material that has been transported from inside the cell into the bile pocket to be measured. The efflux measurements can then facilitate evaluation of biliary clearance, transporter interactions and intracellular concentration.
Until now, the study of the individual role of a transporter in primary hepatocytes and HepaRG cells, which express all of the hepatic transporters, was very difficult. However, by using Sigma-Aldrich CompoZr Zinc Finger Nuclease (ZFN) technology, HepaRG transporter knockout cell lines have been created empowering more accurate research investigations of liver transporters. The B-CLEAR technology enables effective measurement of uptake and efflux into the bile pocket, and the overall integrated effect of transporters and metabolism can also be evaluated.
“The ability to accurately predict drug transporter interactions in the liver is a critical part of developing safer and more efficacious therapies,” said Paul Brooks, Head of Discovery Research Services at Sigma-Aldrich. “We have licensed the B-CLEAR technology to offer a more complete support service for drug transporter assessment, which is in line with BioReliance’s drive to deliver the most innovative advances in in vitro ADME/Tox studies to address customers’ most pressing needs.”
“B-CLEAR technology exclusively allows users to measure compound in the bile pocket, and is the first technology of its kind to enable measuring of physiologic intracellular concentrations. Whether a user is interested in uptake transporter knockouts or efflux transporter knockouts, measuring changes in intracellular concentration is the perfect readout to understand their effects,” said Dr Christopher Black, CEO for Qualyst Transporter Solutions. “We are thrilled to make this licensing agreement with Sigma-Aldrich and BioReliance, and look forward to seeing its positive impact on the pharmaceutical industry.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance